36C10G24Q0105.docx

Combined Synopsis/Solicitation Notice

GENERAL INFORMATION

SET-ASIDE

OPAL | Strategic Acquisition Center

10300 Spotsylvania Ave | STE 400 Fredericksburg VA 22408-2697

POINT OF CONTACT*

Contract Specialist Michael Andrews michael.andrews6@va.gov 678-428-5319

PLACE OF PERFORMANCE

POSTAL CODE

COUNTRY

ADDITIONAL INFORMATION

DESCRIPTION

Combined Synopsis/Solicitation Notice

Solicitation Number:

36C10G24Q0105 Notice Type:

Combined Synopsis/Solicitation Synopsis:

COMBINED SYNOPSIS/SOLICITATION

This is a combined synopsis/solicitation for brand name or equal commercial items prepared in accordance with the format in Federal Acquisition Regulation (FAR) subpart 12.6, “Streamlined Procedures for Evaluation and Solicitation for Commercial Items” as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; offers are being requested and a written solicitation will not be issued.

Solicitation number 36C10G24Q0105 is issued for this combined synopsis/solicitation; this solicitation is being issued as a Request for Quotation (RFQ). This combined synopsis/solicitation incorporates provisions and clauses in effect through Federal Acquisition Circular (FAC) 2024-03, dated February 23, 2024.

Requirement Description:

VA has a requirement to purchase Phacoemulsification Units to deliver patient care at its VA Medical Centers around the country. Phacoemulsification Units are used to break up and remove cataractous lenses of the eye. A cataract is a foggy area in the normally transparent lens that inhibits the transmission of light to the retina and causes a painless blurring of vision and/or glare from lights. Cataracts are caused by changes in the chemical composition of the lens associated with many factors: age, environment, drugs, systemic diseases, traumatic eye injuries, certain diseases of the eye, and genetic or birth defects. Age-related cataracts are the most common. If cataracts are not treated, progressive vision loss leading to significantly impaired sight can occur.

A single award Requirements contract will be awarded IAW FAR 52.211-6 Brand Name or Equal in accordance with all terms, conditions, provisions, specifications, and schedule of this solicitation herein. Offers shall contain the terms for cost/price and technical capabilities of the brand name or equal equipment. The Government reserves the right to award without discussions.

The associated North American Industrial Classification System (NAICS) code for this procurement is 339112 – Surgical and Medical Instrument Manufacturing: 6515 – Medical and Surgical Instruments, Equipment, and Supplies and the associated size standard is 1000 employees. This procurement action is issued as unrestricted full and open.

This acquisition is for a single award Requirements contract in accordance with FAR Part 16.5 for Alcon Centurion® brand name or equal Phacoemulsification Units and related equipment and accessories as identified in ATTACHMENT A – PRICE COST SCHEDULE - NX EQ PHACOEMULSIFICATION UNITS. All interested companies shall provide a quote for all Contract Line Item Numbers (CLINs) listed in ATTACHMENT A – PRICE COST SCHEDULE - NX EQ PHACOEMULSIFICATION UNITS and paragraph 2 below.

The ordering period is for one 12-month base year with four 12-month option years. Delivery is FOB destination. Firm-Fixed Price Orders will be placed against this contract in writing and will provide the delivery locations, delivery dates and exact quantities.

The FAR provision at 52.212-1, Instructions to Offerors – Commercial Products and Commercial Services, applies to this acquisition including attached addenda (ATTACHMENT D) to the provision.

The FAR provision at 52.212-2, Evaluation -- Commercial Products and Commercial Services, and the specific evaluation criteria as attached addenda (ATTACHMENT D) also applies to this acquisition.

The Offeror is to include a completed copy of the provision at 52.212-3, Offeror Representations and Certifications -- Commercial Products and Commercial Services, with its offer.

Clause at 52.212-4, Contract Terms and Conditions -- Commercial Products and Commercial Services, applies to this acquisition and a statement regarding any addenda to the clause. Addendum is attached (ATTACHMENT D).

Clause at 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders -- Commercial Products and Commercial Services, applies to this acquisition and a statement regarding which, if any, of the additional FAR clauses cited in the clause are applicable to the acquisition. Addendum is attached (ATTACHMENT C).

All interested offerors must be registered in the System for Award Management (SAM) prior to submitting a quote. You may access SAM at https://sam.gov/SAM/.

Questions regarding this combined synopsis/solicitation are due via email by 11:59 PM EST on July 18, 2024, to Contract Specialist, Michael Andrews at michael.andrews6@va.gov and Contracting Officer, Sharon Redman at sharon.redman@va.gov. No calls will be accepted.

Quotes are due via email by 11:59 PM EST on July 31, 2024, to Contract Specialist, Michael Andrews at michael.andrews6@va.gov and Contracting Officer, Sharon Redman at sharon.redman@va.gov.

1. SCOPE OF WORK

The Veterans Health Administration (VHA) Non-Expendable Equipment (NX) National Program has identified the Phacoemulsification Units product line as a candidate for inclusion in the National Equipment Catalog (NEC). This will be accomplished via the awarding of a VA-wide (otherwise referred to as “national”) single award Requirements contract.

Phacoemulsification systems are used to break up and remove cataractous lenses of the eye. A cataract is a foggy area in the normally transparent lens that inhibits the transmission of light to the retina and causes a painless blurring of vision and/or glare from lights. Cataracts are caused by changes in the chemical composition of the lens associated with many factors: age, environment, drugs, systemic diseases, traumatic eye injuries, certain diseases of the eye, and genetic or birth defects. Age-related cataracts are the most common. If cataracts are not treated, progressive vision loss leading to significantly impaired sight can occur.

The Contractor must demonstrate the ability to meet all requirements for the solicitation. The objective is to provide Phacoemulsification Units to be used by clinicians throughout the VA medical centers and facilities. The period of performance is for a base of 12-months with four 12-month option periods.

2. REQUIREMENT

This requirement will be IAW FAR clause 52.211-6, “Brand Name or Equal” (BNOE) which requires the Quoter to indicate that each product is being offered as an “equal” product to the Alcon Centurion® Phacoemulsification Units. For each equal product, the Quoter must include a description reflecting the salient characteristics (SC) and level of quality that will satisfy the salient physical, functional, or performance characteristics of the equal product(s) specified in the solicitation. The Quoter must also clearly identify the item by brand name (if any) and make/model number. Finally, the Quoter must include descriptive literature, such as illustrations, drawings, or a clear reference to previously furnished descriptive data or information available to the Contracting Officer, and clearly describe any modifications it plans to make to a product to make it conform to the solicitation requirements.

The Department of Veterans Affairs (VA) is seeking vendors who can provide Alcon Centurion® Brand Name or Equal (BNOE) Phacoemulsification Units as listed above or equal commodities which meet all the following salient characteristics.

The following SCs apply to CLINs 0001 - 0004

Vendors may offer any product solution or configuration so long as they meet the salient characteristics. Products offered in the technical volume must be captured on the Vendor’s pricing volume (ATTACHMENT A, Price Cost Schedule) of the solicitation. Vendors may offer any additional ancillary products which they deem to be essential to the functionality of the proposed solution; these items must be captured in the Vendor’s pricing volume with a quantity of zero.

The following attachments are incorporated by reference. All criteria outlined in the attachments are applicable to this Combined Synopsis/Solicitation Notice.

See attached document: ATTACHMENT A - PRICE COST SCHEDULE - NX EQ PHACOEMULSIFICATION UNITS See attached document: ATTACHMENT B - CONTRACT ADMINISTRATION - NX EQ PHACOEMULSIFICATION UNITS.

See attached document: ATTACHMENT C - CONTRACT CLAUSES - NX EQ PHACOEMULSIFICATION UNITS See attached document: ATTACHMENT D - SOLICITATION PROVISIONS - NX EQ PHACOEMULSIFICATION UNITS.

See attached document: ATTACHMENT E - REPORTING TOOL - NX EQ PHACOEMULSIFICATION UNITS

See attached document: ATTACHMENT A - PRICE COST SCHEDULE - PHACOEMULSIFICATION UNITS - 36C10G24Q0105.

See attached document: ATTACHMENT B - CONTRACT ADMINISTRATION - PHACOEMULSIFICATION UNITS - 36C10G24Q0105.

See attached document: ATTACHMENT C - CONTRACT CLAUSES - PHACOEMULSIFICATION UNITS - 36C10G24Q0105.

See attached document: ATTACHMENT D - SOLICITATION PROVISIONS - PHACOEMULSIFICATION UNITS -36C10G24Q0105.

See attached document: ATTACHMENT E - SALES REPORTING TOOL - PHACOEMULSIFICATION UNITS -36C10G24Q0105.

Page 1 of

Page 1 of Page 1 of Page 1 of